Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Igg-Like T Cell Engager Binding To Dll3 And Cd3 – Application in ...
DLL3 trispecific binds to CD3 and CD137 competitively. A, Activation of ...
Assessment of DLL3 and CD3 Expression in Pediatric Tumor FFPE Samples ...
Henlius’ DLL3 × CD3 × CD28 Tri-specific TCE: An Integration of ...
US20170037130A1 - Antibody constructs for dll3 and cd3 - Google Patents
DLL3 – A Breakthrough Target for Small Cell Lung Cancer Therapy-DIMA ...
Anti-DLL3 and CD3(tarlatamab biosimilar) BsAb-DLL3 and CD3 Biosimilar ...
Immunotherapeutic Targeting and PET Imaging of DLL3 — Chou Lab @ UCSF
DLL3 regulates Notch signaling in small cell lung cancer: iScience
Anti-DLL3(tarlatamab without CD3 biosimilar) mAb-DLL3阳性参照抗体-适用于Flow Cyt ...
DLL3 Is a Prognostic and Potentially Predictive Biomarker for ...
DLL3 expression in normal and tumor tissue. DLL3 protein expression via ...
Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in ...
Structural and functional insights into CD3 bispecific antibodies ...
Near infrared photoimmunotherapy targeting DLL3 for small cell lung ...
Full article: Phase I trial of the DLL3/CD3 bispecific T-cell engager ...
Mechanism of Action (MOA) | IMDELLTRA® (tarlatamab-dlle) HCP
DLL3/CD3 T-cell engager | InOncology – Boehringer Ingelheim
1.7亿美元首付：第一三共从默沙东引进一款DLL3/CD3双抗_财富号_东方财富网
勃林格殷格翰小细胞肺癌新药DLL3/CD3双抗II期临床试验在中国获批-美通社PR-Newswire
安进大胜「肺癌之王」
重磅！Amgen首创双抗Tarlatamab (CD3+DLL3)获批上市 - 知乎
记住所有FDA生物药 | DLL3×CD3双抗 | Tarlatamab 塔拉塔单抗 | 广泛期小细胞肺癌 - 知乎
读书报告 | 靶向DLL3和CD3+T细胞的双特异性Tarlatamab治疗复发性小细胞肺癌的I期临床研究-MedSci.cn
突破：首个实体瘤TCE双抗获批上市 今日，Amgen宣布，FDA加速批准其靶向DLL3/CD3的双特异抗体tarlatamab上市，用于治疗 ...
DLL3/CD3 bispecific antibody: mechanism of action - YouTube
Frontiers | Advances in DLL3-targeted therapies for small cell lung ...
Tarlatamab Biosimilar Antibody (Recombinant DLL3-CD3 BiTE-class ...
DLL3：多赛道进击小细胞肺癌 - 知乎
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell ...
2023 WCLC | 小细胞肺癌的探索：DLL3靶向药物，B7-H3 ADC 小细胞肺癌（SCLC）约占肺癌的14%，且预后不良，广泛期患者 ...
2022 WCLC | 靶向DLL3/CD3双抗Tarlatamab治疗SCLC的I期数据更新医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
二线大胜：安进启动DLL-3/CD3双抗第2项小细胞肺癌一线三期临床
针对小细胞肺癌靶向DLL3的新疗法-MedSci.cn
靶向DLL3，安进/百济神州递交双特异性T细胞结合器临床申请 3月15日，中国国家药监局药品审评中心（CDE）官网公示， 安进 （Amgen ...
Bispecific T cell engager (BiTE) tumor killing assay I CRO Immuno-Oncology
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is ...
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces ...
实体瘤突破：安进DLL3/CD3双抗获FDA批准 Armstrong 2024年5月16日，FDA加速批准 安进 DLL3/CD3双抗 ...
塔拉妥单抗(TARLATAMAB-DLLE) - 药物靶点：CD3 x DLL3_在研适应症：小细胞肺癌，广泛期小细胞肺癌，局限期小细胞肺癌 ...
2024年5月16日FDA加速批准了CD3和DLL3双靶点抑制剂塔拉妥单抗(AMG757、Tarlatamab-dlle、Imdelltra ...
CD3双抗：肿瘤治疗的突破与自免领域的新机遇
安进DLL3/CD3双抗获FDA批准上市医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
NEJM丨小细胞肺癌，靶向新药Tarlatamab（DLL3/CD3双抗）显著延长生存时间 - 知乎
AACR 2025: Preclinical evaluation of CD3/DLL3 bispecific antibody in ...
【疗效显著】安进DLL3/CD3双抗临床3期取得重大突破 - 知乎
超给力！Tarlatamab治疗晚期小细胞肺癌，超一半患者有效！-出国看病-盛诺一家
[PDF] A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces ...
DLL3/CD3 T-cell Engager | Clinical Research | InOncology
DLL3/CD3双抗「塔拉妥单抗」国内上市申请获拟优先审评，用于广泛期小细胞肺癌三线及后线治疗 - 知乎
Delta‐like ligand 3: A promising target against small cell lung cancer ...
美国APExBIO中文官网 - Anti-CD3/DLL3 Antibody (Tarlatamab)
安进宣布DLL3/CD3双抗上市申请获FDA优先评审资格医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
TCE In Vitro Evaluation Platform: Comprehensive Assessment from Target ...
Targeting DLL3: Innovative Strategies for Tumor Treatment
Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small ...
用于治疗癌症的DLL3/CD3结合蛋白的制作方法
安进/百济神州DLL3/CD3双抗在华申报临床 3月15日， 安进 递交Tarlatamab的临床试验获得CDE受理。Tarlatamab ...
安进：DLL3/CD3双抗递交上市申请，获优先审评资格 Armstrong 2023年12月13日， 安进 宣布DLL3/CD3双抗 ...
Molecular architecture of the αβ T cell receptor–CD3 complex | PNAS
Frontiers | Identification of DLL3-related genes affecting the ...
Assessment of DLL3/CD3 T-cell Engager Obrixtamig for Neuroendocrine ...
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in ...
Figure 2 from Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T ...
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients ...
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in ...
小细胞肺癌的治疗靶点DLL3
